Michael Kalos
Direktor/Vorstandsmitglied bei IMV INC.
Vermögen: - $ am 31.12.2023
Profil
Michael Kalos is an Independent Director at IMV, Inc. and a Managing Director at Next Pillar Consulting, LLC.
He was formerly the Chief Scientific Officer at Eli Lilly & Co., the Vice President-Immunooncology at Janssen Pharmaceuticals, Inc., and the Executive VP & Head-Research & Development at Arsenal Biosciences, Inc. He holds a doctorate degree from the University of Minnesota.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
IMV INC.
-.--% | 31.03.2023 | 0 ( -.--% ) | - $ | 31.12.2023 |
Aktive Positionen von Michael Kalos
| Unternehmen | Position | Beginn |
|---|---|---|
| IMV INC. | Direktor/Vorstandsmitglied | 11.05.2021 |
| Next Pillar Consulting, LLC | Vorstandsvorsitzender | - |
Ehemalige bekannte Positionen von Michael Kalos
| Unternehmen | Position | Ende |
|---|---|---|
Janssen Pharmaceuticals, Inc.
 Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Corporate Officer/Principal | - |
| ELI LILLY AND COMPANY | Technik-/Wissenschafts-/F&E-Leiter | - |
Arsenal Biosciences, Inc.
 Arsenal Biosciences, Inc. Packaged SoftwareTechnology Services Arsenal Biosciences, Inc. discovers, develops, and commercializes curative immune cell therapies. It offers cell therapy, cloud computing, computational biology, genome engineering, machine learning, software engineering, and synthetic immunology. The company was founded by Ken E. Drazan, Bradley E. Bernstein, W. Nicholas Haining, Theo Roth, Kole T. Roybal, and E. John Wherry and is headquartered in San Francisco, CA. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Michael Kalos
| University of Minnesota | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| IMV INC. | Health Technology |
| ELI LILLY AND COMPANY | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Arsenal Biosciences, Inc.
Arsenal Biosciences, Inc. Packaged SoftwareTechnology Services Arsenal Biosciences, Inc. discovers, develops, and commercializes curative immune cell therapies. It offers cell therapy, cloud computing, computational biology, genome engineering, machine learning, software engineering, and synthetic immunology. The company was founded by Ken E. Drazan, Bradley E. Bernstein, W. Nicholas Haining, Theo Roth, Kole T. Roybal, and E. John Wherry and is headquartered in San Francisco, CA. | Technology Services |
| Next Pillar Consulting, LLC | |
Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Health Technology |
